Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Chembio nets $15mm via FOPO

Executive Summary

Infectious disease-focused Chembio Diagnostics Inc. netted $15mm through a registered public offering of 2.37mm common shares at $6.75. Chembio will use the proceeds to fund its proposed $5.5mm acquisition of opTricon, an OEM offering handheld analyzers for rapid diagnostic tests. Additional funds will help broaden US manufacturing automation and expanding and improving facilities.
Deal Industry
  • Biotechnology
  • In Vitro Diagnostics
    • Chemistry, Immunoassay
Deal Status
  • Final
Deal Type
  • Financing
    • FOPO

Related Companies